Export financials
REGENXBIO (RGNX)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.

REGENXBIO Income Statement 2025-2011 | RGNX
Brief overview of income trends at REGENXBIO
This overview is based on financial performance over the past five years. The revenue attributed to REGENXBIO moved from 155 million dollars to 170 million dollars between the two endpoints. Overall revenue changed by +10.3%, equal to an annualized rate of about 2%. The revenue trend is close to stagnation.
The operating result measured by EBITDA moved from −$111 million to −$146 million, or −31.4%. Operating performance weakened relative to revenue. At the operating-margin level, the figure shifted from −71.7% to −85.4%. Cost pressure reduced operating profitability.
Comparing the endpoints shows a move from −111 million dollars to −194 million dollars. The period ended with a larger loss than it began with.
The five-year change in capitalization reached −70.9%: from 1.5 billion dollars to 444 million dollars. Lower capitalization reflects weaker investor expectations.
What the figures show
The current trajectory does not yet confirm a sustainable recovery. Caution is warranted because of weak sales momentum, a declining EBITDA margin and a weaker market valuation. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement REGENXBIO
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
444 M | 426 M | 872 M | 958 M | 1.11 B | 1.53 B | 1.63 B | 1.44 B | 844 M | 479 M | 128 M | - | - | - | - |
Shares |
51.6 M | 49.5 M | 43.7 M | 43.2 M | 42.4 M | 37.3 M | 36.7 M | 33.4 M | 29.9 M | 26.4 M | 9.17 M | - | - | - | - |
Historical Prices |
8.6 | 8.6 | 19.9 | 22.2 | 26.2 | 40.9 | 40 | 51.7 | 28.4 | 18.4 | 12.1 | - | - | - | - |
Net Income |
-194 M | -227 M | -263 M | -280 M | 128 M | -111 M | -94.7 M | 99.9 M | -73.2 M | -63 M | -22.8 M | -4 M | -5.39 M | - | - |
Revenue |
170 M | 83.3 M | 90.2 M | 113 M | 470 M | 155 M | 35.2 M | 219 M | 10.4 M | 4.59 M | 7.59 M | 6.12 M | 6.09 M | - | - |
Cost of Revenue |
- | 33.6 M | 37.2 M | 54.5 M | 51.8 M | 35.7 M | 8.24 M | 9.64 M | 1.71 M | - | - | - | - | - | - |
Gross Profit |
- | 49.8 M | 53 M | 58.2 M | 419 M | 119 M | 27 M | 209 M | 8.68 M | 3.63 M | 6.08 M | 5.11 M | 5.76 M | - | - |
Operating Income |
-161 M | -233 M | -268 M | -263 M | 160 M | -119 M | -149 M | 88.1 M | -75.9 M | -65.3 M | -23.1 M | -3.68 M | -4.78 M | - | - |
Interest Expense |
- | - | 6.86 M | 23.3 M | 26.3 M | 771 K | - | - | - | - | 20 K | 321 K | 611 K | - | - |
EBITDA |
-146 M | -217 M | -251 M | -250 M | 170 M | -111 M | -142 M | 92.1 M | -73.2 M | -64.8 M | -23 M | -3.65 M | -4.76 M | - | - |
Operating Expenses |
161 M | 283 M | 321 M | 321 M | 259 M | 238 M | 176 M | 121 M | 84.6 M | 69 M | 29.2 M | 8.76 M | 10.5 M | - | - |
General and Administrative Expenses |
82.9 M | 76.6 M | 88.5 M | 85.3 M | 79.3 M | 63.8 M | 51.8 M | 36.8 M | 27.2 M | 23.6 M | 11.9 M | 3.85 M | 5.47 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement REGENXBIO
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
65.3 M | 52.8 M | 52.4 M | 60 M | 51.7 M | 51.5 M | 51.4 M | 458 K | 50.8 M | 50.6 M | 45.7 M | 90 K | 43.9 M | 43.5 M | 43.5 M | 43.1 M | 43.3 M | 43.1 M | 42.9 M | 42.4 M | 42.6 M | 42.5 M | 41.8 M | 47 M | 37.3 M | 37.3 M | 37.1 M | 72 K | 36.8 M | 36.7 M | 36.4 M | 851 K | 34 M | 32.1 M | 31.6 M | 438 K | 30.9 M | 30.7 M | 26.7 M | 26.5 M | 26.5 M | 26.4 M | 26.3 M | 26.3 M | 4.81 M | 2.71 M | 2.64 M | 2.64 M | 2.64 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-40.7 M | 22.7 M | -90.1 M | -67.1 M | -61.9 M | -70.9 M | 6.08 M | -51.2 M | -59.6 M | -53 M | -63.3 M | -62.9 M | -61.9 M | -72.1 M | -66.7 M | -59.9 M | -75.5 M | -68.2 M | -76.7 M | 294 M | -58.4 M | -57.6 M | -50.1 M | -46.2 M | 8.79 M | -33.8 M | -40 M | -26.5 M | -34.6 M | -1.46 M | -32.2 M | 4.31 M | -19.2 M | 10.6 M | 104 M | -16 M | -20.7 M | -14.5 M | -22 M | -19.6 M | -18.2 M | -14.4 M | -10.8 M | -5.18 M | -7.33 M | -6.29 M | -4.01 M | -2.33 M | -1.79 M | -672 K | 795 K | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
9.16 M | 108 M | 6.39 M | 30.3 M | 29.7 M | 21.4 M | 89 M | 21.2 M | 24.2 M | 22.3 M | 15.6 M | 22.2 M | 28.9 M | 20 M | 19.1 M | 31.3 M | 26.5 M | 32.6 M | 22.2 M | 403 M | 30.3 M | 18.4 M | 18.3 M | 21.4 M | 98.8 M | 15.4 M | 9.98 M | 11.8 M | 9.18 M | 4.42 M | 884 K | 40.8 M | 4 M | 40 M | 132 M | 2.04 M | 1.34 M | 6.56 M | 455 K | 1.7 M | 125 K | 2.38 M | 393 K | 4.44 M | 1.14 M | 1.36 M | 644 K | 1.15 M | 483 K | 1.55 M | 2.94 M | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
- | - | - | - | - | - | - | 6.32 M | 12.4 M | 10.6 M | 4.28 M | 11.2 M | 12.4 M | 9.48 M | 4.11 M | 12.8 M | 13.1 M | 13 M | 15.7 M | 23.1 M | 14.1 M | 9.82 M | 4.85 M | 10.3 M | 17.4 M | 4.68 M | 3.41 M | 3.79 M | 2.49 M | 1.93 M | 29 K | 2.84 M | 517 K | 3.87 M | 2.41 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | 14.9 M | 11.8 M | 11.7 M | 11.3 M | 11 M | 16.5 M | 10.5 M | 15 M | 18.6 M | 13.4 M | 19.7 M | 6.5 M | 380 M | 16.1 M | 8.61 M | 13.4 M | 11.2 M | 81.4 M | 10.8 M | 6.57 M | 7.98 M | 6.69 M | 2.5 M | 855 K | 37.9 M | 3.48 M | 36.2 M | 130 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-35.5 M | 29.3 M | -83.4 M | -57.6 M | -52.4 M | -63.3 M | 12.1 M | -51.4 M | -62.1 M | -56 M | -63.9 M | -63.9 M | -65 M | -73.1 M | -66.2 M | -57.8 M | -71 M | -62.5 M | -71.5 M | 314 M | -57.3 M | -52.2 M | -44 M | -53.7 M | 14 M | -41.8 M | -37.7 M | -40.3 M | -35.9 M | -36.9 M | -35.9 M | 2.45 M | -22.7 M | 6.35 M | 102 M | -16.6 M | -21.3 M | -15.1 M | -22.9 M | - | -18.7 M | -15 M | -11.3 M | - | -7.35 M | -6.3 M | -3.99 M | - | -1.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
- | - | - | - | - | - | - | - | - | 449 K | 1.97 M | 1.36 M | 1.62 M | 1.12 M | 2.76 M | 4.31 M | 5.95 M | 6.86 M | 6.13 M | 6.5 M | 6.71 M | 6.37 M | 6.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 483 K | - | 20 K | 20 K | 20 K | - | 92 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-35.5 M | 33 M | -79.5 M | -53.8 M | -48.5 M | -59.4 M | 16.1 M | -47.3 M | -58.1 M | -52 M | -59.7 M | -59.6 M | -60.6 M | -68.7 M | -62 M | -53.6 M | -67.5 M | -59.9 M | -68.9 M | 316 M | -54.5 M | -50 M | -42.1 M | -51.5 M | 16.1 M | -39.7 M | -35.7 M | -38.4 M | -34 M | -35.1 M | -34.3 M | 3.76 M | -21.8 M | 7.25 M | 103 M | -15.9 M | -20.6 M | -14.4 M | -22.4 M | - | -18.4 M | -14.9 M | -11.2 M | - | -7.3 M | -6.28 M | -3.99 M | - | -1.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
- | -29.3 M | 83.4 M | - | 52.4 M | 63.3 M | -12.1 M | 66.3 M | 73.9 M | 67.8 M | 75.2 M | 74.9 M | 81.5 M | 83.6 M | 81.2 M | 76.3 M | 84.5 M | 82.2 M | 78 M | 66.7 M | 73.5 M | 60.8 M | 57.5 M | 64.8 M | 67.5 M | 52.6 M | 44.3 M | 48.3 M | 42.6 M | 39.4 M | 36.8 M | 35.5 M | 26.2 M | 29.8 M | 28 M | 16.6 M | 21.3 M | 15.1 M | 22.9 M | - | - | 15 M | 11.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
20.6 M | 21.6 M | 21.3 M | 22.4 M | 20.3 M | 19.9 M | 20.3 M | 20.1 M | 19.4 M | 18.9 M | 18.3 M | 19.1 M | 23.1 M | 23.7 M | 22.6 M | 21.2 M | 20.9 M | 20.8 M | 22.3 M | 22 M | 21 M | 18.4 M | 17.8 M | 17.6 M | 15.9 M | 15.6 M | 14.8 M | 14.4 M | 12.4 M | 13.4 M | 11.6 M | 11.1 M | 9.01 M | 8.32 M | 8.38 M | 4.81 M | 9.44 M | 6.36 M | 6.62 M | 5.74 M | 6.2 M | 6.17 M | 5.48 M | 4.23 M | 2.57 M | 3.4 M | 1.72 M | - | 1.07 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company REGENXBIO (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Biotechnology industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Arcturus Therapeutics Holdings
ARCT
|
$ 7.42 | -2.37 % | $ 203 M | ||
|
Aurinia Pharmaceuticals
AUPH
|
$ 14.7 | -1.28 % | $ 1.98 B | ||
|
Autolus Therapeutics plc
AUTL
|
$ 0.91 | -6.96 % | $ 242 M | ||
|
Atea Pharmaceuticals
AVIR
|
$ 3.97 | 0.89 % | $ 324 M | ||
|
Axsome Therapeutics
AXSM
|
$ 129.32 | -4.69 % | $ 6.43 B | ||
|
BridgeBio Pharma
BBIO
|
$ 75.96 | -2.84 % | $ 14.5 B | ||
|
BioCryst Pharmaceuticals
BCRX
|
$ 7.23 | -1.3 % | $ 1.52 B | ||
|
Bicycle Therapeutics plc
BCYC
|
$ 2.89 | -5.25 % | $ 200 M | ||
|
Benitec Biopharma
BNTC
|
$ 7.95 | -2.4 % | $ 370 M | ||
|
DiaMedica Therapeutics
DMAC
|
$ 8.24 | 2.74 % | $ 387 M | ||
|
Insmed Incorporated
INSM
|
$ 141.06 | -2.35 % | $ 28.1 B | ||
|
Iovance Biotherapeutics
IOVA
|
$ 6.9 | -5.61 % | $ 2.47 M | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
$ 4.64 | 17.17 % | $ 56.6 M | ||
|
InMed Pharmaceuticals
INM
|
$ 15.56 | 13.57 % | $ 64.8 M | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$ 12.36 | -9.55 % | $ 799 M | ||
|
Immutep Limited
IMMP
|
$ 3.11 | -9.06 % | $ 4.53 B | ||
|
Jazz Pharmaceuticals plc
JAZZ
|
$ 228.26 | -3.46 % | $ 13.9 B | ||
|
BeyondSpring
BYSI
|
$ 0.33 | -24.42 % | $ 13.6 M | ||
|
Cabaletta Bio
CABA
|
$ 0.94 | -7.24 % | $ 94.5 M | ||
|
Johnson & Johnson
JNJ
|
$ 270.2 | 1.18 % | $ 650 B | ||
|
Cue Biopharma
CUE
|
$ 4.2 | -6.67 % | $ 398 M | ||
|
C4 Therapeutics
CCCC
|
$ 2.49 | 1.84 % | $ 206 M | ||
|
Codexis
CDXS
|
$ 1.0 | -5.17 % | $ 87.1 M | ||
|
Kamada Ltd.
KMDA
|
$ 7.75 | -1.02 % | $ 447 M | ||
|
Compugen Ltd.
CGEN
|
$ 1.83 | -2.66 % | $ 171 M | ||
|
Coherus BioSciences
CHRS
|
$ 0.37 | -4.06 % | $ 43.3 M | ||
|
Armata Pharmaceuticals
ARMP
|
$ 3.06 | 2.68 % | $ 111 M | ||
|
Celldex Therapeutics
CLDX
|
$ 27.36 | -2.15 % | $ 1.82 B | ||
|
Cellectis S.A.
CLLS
|
$ 0.9 | -9.7 % | $ 90.3 M | ||
|
Lineage Cell Therapeutics
LCTX
|
$ 0.78 | -4.87 % | $ 179 M | ||
|
Edesa Biotech
EDSA
|
$ 2.01 | -7.59 % | $ 11.4 M | ||
|
Eli Lilly and Company
LLY
|
$ 1 345.4 | -0.44 % | $ 1.21 T | ||
|
Collegium Pharmaceutical
COLL
|
$ 24.73 | -1.9 % | $ 783 M | ||
|
Evogene Ltd.
EVGN
|
$ 0.32 | 1.02 % | $ 2.52 M | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
$ 2.05 | -15.81 % | $ 27.3 M | ||
|
Forte Biosciences
FBRX
|
$ 76.99 | 0.03 % | $ 997 M | ||
|
Curis
CRIS
|
$ 0.44 | -6.31 % | $ 5.79 M | ||
|
CorMedix
CRMD
|
$ 5.25 | 4.23 % | $ 378 K | ||
|
Larimar Therapeutics
LRMR
|
$ 3.07 | -4.66 % | $ 255 M | ||
|
Champions Oncology
CSBR
|
$ 4.34 | -1.36 % | $ 60 M | ||
|
Mesoblast Limited
MESO
|
$ 10.9 | -2.5 % | $ 13.2 B | ||
|
Mirum Pharmaceuticals
MIRM
|
$ 96.15 | 0.67 % | $ 4.83 B | ||
|
MannKind Corporation
MNKD
|
$ 3.85 | -2.66 % | $ 1.18 B | ||
|
Dyadic International
DYAI
|
$ 0.29 | -6.53 % | $ 10.5 M | ||
|
Merck & Co.
MRK
|
$ 133.34 | 0.4 % | $ 334 B | ||
|
Moderna
MRNA
|
$ 195.25 | -2.05 % | $ 76 B | ||
|
NuCana plc
NCNA
|
$ 0.75 | 4.39 % | $ 8.42 B | ||
|
Novartis AG
NVS
|
$ 150.51 | -0.47 % | $ 292 B | ||
|
Puma Biotechnology
PBYI
|
$ 7.05 | -1.05 % | $ 353 M | ||
|
Fulcrum Therapeutics
FULC
|
$ 3.69 | -0.67 % | $ 281 M |